Camille MacMillin/STAT

STAT+ | The FDA’s rebuilding effort is running into a new challenge

After losing 5,000 staffers, FDA plans to hire 2,000 are delayed by issues in new centralized hiring center. 'A completely self-created problem.'

By Margaret Manto

Kennedy moves to revive preventive services panel with new members, after months of vacancies

Robert F. Kennedy Jr. named eight new members to the influential panel, which hasn't met in more than a year.

By Chelsea Cirruzzo, Elizabeth Cooney,and Sarah Todd

New lawsuit argues NIH violated First Amendment rights of grant applicants

The case alleges that the National Institutes of Health infringed on speech freedoms by screening grant applications for specific terms.

By Anil Oza

MIRIAM MASLO/SCIENCE PHOTO LIBRARY

STAT+ | Why do ‘never smokers’ get lung cancer? In some cases, rare genetic variant may be a factor

Researchers found that people carrying a rare inherited EGFR variant (T790M) had dramatically higher odds of lung cancer, especially if they never smoked.

By Andrew Joseph

STAT+ | FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease

Fayuvi, which was developed by Ultragenyx, is the first treatment for the condition, sometimes known as childhood Alzheimer’s.

By Jason Mast

STAT+ | England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal

The agreement between England and AstraZeneca stems from changes in how the U.K. values medicines made as part of a trade deal with the U.S.

By Andrew Joseph

Molly Ferguson/STAT

STAT+ | A Sellas immunotherapy study, long delayed, will end in failure

The prediction is based on delays — never a good sign — that have raised significant doubts about the drug's efficacy.

By Adam Feuerstein

Opinion: What happened to oppositional defiant disorder?

Oppositional defiant disorder is becoming less common in children. The shift reflects a changing view of whether difficult behavior is something a child won’t do or can’t do.

By Lawrence Diller